RGRussell P. Goodman

Russell P. Goodman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Russell P. Goodman has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alcohol-induced hepatic secretome identifies the FSTL3–activin A–ActRII axis as a therapeutic target in alcohol-related liver disease

    by Gloria Alvarez-Sola, Nahid Arghiani, Kaihua Liu, Angela Shih, Emma Butler, Jay Luther, Esperance A Schaefer, Melissa Brown, Wei Zhang, Zhaoli Sun, et al.

  • Open Access

    LiRNA: An Interactive Atlas of Human Liver RNAseq Databases

    by Gloria Alvarez Sola, Nirajan Shrestha, Raquel Benede Ubieto, Byungchang Jin, Timothy J. Kendall, Jonathan A. Fallowfield, Russell P. Goodman


  • A genetically encoded bifunctional enzyme mitigates redox imbalance and lipotoxicity

    by Xingxiu Pan, Subrata Munan, Austin L. Zuckerman, Andrew Pon, Niklas B. Thompson, Rasangi M. Perera, Nirajan Shrestha, Sara Violante, Justin R. Cross, Russell P. Goodman, et al.

    Dihydroxyacetone phosphate (DHAP), glycerol-3-phosphate (Gro3P) and reduced/oxidized nicotinamide adenine dinucleotide (NADH/NAD⁺) are key metabolites of the Gro3P shuttle, which transfers reducing equivalents between the cytosol and mitochondria. Targeted activation of Gro3P biosynthesis has recently emerged as a promising strategy to alleviate reductive stress. However, because Gro3P constitutes the backbone of triglycerides, its accumulation can promote extensive lipogenesis. Here we show that a genetically encoded tool based on a di-domain glycerol-3-phosphate dehydrogenase from the alga Chlamydomonas reinhardtii (CrGPDH) effectively operates both the alternative Gro3P shunt, which regenerates NAD⁺ while converting DHAP to Gro3P, and the glycerol shunt, which converts Gro3P to glycerol and inorganic phosphate, across transformed and primary mammalian cell cultures as well as mouse liver. CrGPDH expression supported proliferation of cancer cells under respiratory chain inhibition or hypoxia, as well as patient-derived fibroblasts with mitochondrial dysfunction. Moreover, CrGPDH decreased triglyceride levels in kidney cancer cell lines and reversed ethanol-induced triglyceride accumulation in mouse liver. Thus, CrGPDH represents a promising xenotopic tool to alleviate redox imbalance and associated impaired lipogenesis in conditions ranging from primary mitochondrial diseases to steatosis.


  • Open Access

    Glycerol-3-phosphate activates ChREBP, FGF21 transcription and lipogenesis in citrin deficiency

    by Vinod Tiwari, Byungchang Jin, Olivia Sun, Edwin D. J. Lopez Gonzalez, Min-Hsuan Chen, Xiwei Wu, Hardik Shah, Andrew Zhang, Mark A. Herman, Cassandra N. Spracklen, et al.

    Citrin deficiency (CD) is caused by the inactivation of SLC25A13, a mitochondrial membrane protein required to move electrons from cytosolic NADH to the mitochondrial matrix in hepatocytes. People with CD do not like sweets. Here we show that SLC25A13 loss causes the accumulation of glycerol-3-phosphate (G3P), which activates the carbohydrate response element-binding protein (ChREBP) to transcribe FGF21, which acts in the brain to restrain intake of sweets and alcohol and to transcribe key genes driving lipogenesis. Mouse and human data suggest that G3P–ChREBP is a mechanistic component of the Randle Cycle that contributes to metabolic-dysfunction-associated steatotic liver disease and forms part of a system that communicates metabolic states from the liver to the brain in a manner that alters food and alcohol choices. The data provide a framework for understanding FGF21 induction in varied conditions, suggest ways to develop FGF21-inducing drugs and suggest potential drug candidates for lean metabolic-dysfunction-associated steatotic liver disease and support of urea cycle function in CD.


  • Open Access

    Integrating hepatology with addiction care for inpatients with alcohol use disorder reduces future liver-related events

    by Paul George, Chantelle Marshall, Wei Zhang, Russell Goodman, Michael Butler, Suraj J. Patel, Mack Mitchell, Esperance Schaefer, Jay Luther

    Background: Strategies to identify patients with early alcohol-associated liver disease (ALD), prior to the development of liver-related decompensated events, and promote alcohol therapy engagement in these patients are urgently needed to stem the rising tide of mortality associated with ALD. Methods: We compared the rate of incident liver-related decompensating events in hospitalized patients with alcohol use disorder (AUD) seen either by an integrated hepatology and addiction care approach or addiction care alone at 2 academic medical centers. Cox proportional hazards regression model and a Kaplan–Meier analysis were used. Findings: An integrated approach of hepatology and addiction care is associated with a reduced likelihood of future liver-related decompensating events in hospitalized patients with AUD. This finding correlated with an increased uptake of medical alcohol therapy and a reduced likelihood of an alcohol-associated readmission. Integrated hepatology and addiction care for hospitalized AUD patients may help reduce the progression of ALD.


  • Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease

    by Richard Parker, Guru Aithal, Michael Allison, Mayur Brahmania, Ewan Forrest, Hannes Hagström, Brian T. Lee, Soyoun J. Park, Anne McCune, Timothy Morgan, et al.

    INTRODUCTION: Alcohol-associated liver disease (ALD) is a common cause of morbidity and premature mortality. Most prognostic scores have been defined in the short term. We used a large retrospective cohort of patients with ALD to describe the natural history of ALD and to define risk prediction in the longer term, taking nonliver mortality into account. METHODS: The WALDO cohort includes 734 patients with biopsy-proven ALD. Prognostic scores were assessed with dynamic area under the curve and C-index. Risk estimates for morbidity and mortality were derived for the model for end-stage liver disease (MELD) and validated in an external cohort. RESULTS: During a median follow-up of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 patients died from nonliver causes. Outcomes varied across the spectrum of ALD: The cumulative incidence of liver-related death or LT in people with decompensated cirrhosis or alcohol-associated hepatitis was 47% and 40%, respectively, compared with 7.4% in patients without cirrhosis and 13% in compensated cirrhosis. MELD was the best predictor of outcomes: (area under the curve for mortality/LT at 1 year was 0.853), although MELD3.0 and the Child-Turcotte-Pugh score performed similarly. Risk of liver-related outcomes were tabulated for integer values of the MELD score. Risk estimates based on the MELD were well calibrated in an external cohort. DISCUSSION: These data illustrate the natural history of ALD and define the risks of outcomes based on the MELD score across the spectrum of disease.


  • Open Access

    Reply: Is nesting addiction medicine and hepatology care in the outpatient setting worthwhile? A retrospective case series at a single tertiary center

    by Rachael Mahle, Paige McLean Diaz, Chantelle Marshall, Russell P. Goodman, Esperance Schaefer, Jay Luther

  • Open Access

    Proteomics identifies complement protein signatures in patients with alcohol-associated hepatitis

    by Moyinoluwa Taiwo, Emily Huang, Vai Pathak, Annette Bellar, Nicole Welch, Jaividhya Dasarathy, David Streem, Craig J. McClain, Mack C. Mitchell, Bruce A. Barton, et al.

    Diagnostic challenges continue to impede development of effective therapies for successful management of alcohol-associated hepatitis (AH), creating an unmet need to identify noninvasive biomarkers for AH. In murine models, complement contributes to ethanol-induced liver injury. Therefore, we hypothesized that complement proteins could be rational diagnostic/prognostic biomarkers in AH. Here, we performed a comparative analysis of data derived from human hepatic and serum proteome to identify and characterize complement protein signatures in severe AH (sAH). The quantity of multiple complement proteins was perturbed in liver and serum proteome of patients with sAH. Multiple complement proteins differentiated patients with sAH from those with alcohol cirrhosis (AC) or alcohol use disorder (AUD) and healthy controls (HCs). Serum collectin 11 and C1q binding protein were strongly associated with sAH and exhibited good discriminatory performance among patients with sAH, AC, or AUD and HCs. Furthermore, complement component receptor 1-like protein was negatively associated with pro-inflammatory cytokines. Additionally, lower serum MBL associated serine protease 1 and coagulation factor II independently predicted 90-day mortality. In summary, meta-analysis of proteomic profiles from liver and circulation revealed complement protein signatures of sAH, highlighting a complex perturbation of complement and identifying potential diagnostic and prognostic biomarkers for patients with sAH.


  • ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits

    by Charandeep Singh, Byungchang Jin, Nirajan Shrestha, Andrew L. Markhard, Apekshya Panda, Sarah E. Calvo, Amy Deik, Xingxiu Pan, Austin L. Zuckerman, Amel Ben Saad, et al.